Simply Wall St.
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus
📈
AI Sentiment
Highly Positive
8/10
- Home
- EYPT
as of 03-23-2026 3:52pm EST
$12.86
$0.31
-2.35%
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.5B | IPO Year: | 2005 |
| Target Price: | $31.80 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.17 | EPS Growth: | -36.64 |
| 52 Week Low/High: | $3.91 - $19.11 | Next Earning Date: | 03-04-2026 |
| Revenue: | $7,539,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -85.24% | Revenue Growth (next year): | 1031.72% |
| P/E Ratio: | -4.15 | Index: | N/A |
| Free Cash Flow: | -243390000.0 | FCF Growth: | N/A |
AI-Powered EYPT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.13%
76.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
Duker Jay S.
Buy
President and CEO
EYPT Mar 16, 2026
Avg Cost/Share
$13.15
Shares
1,500
Total Value
$19,723.80
Owned After
100,665
SEC Form 4
Ribeiro Ramiro
Sell
Chief Medical Officer
EYPT Mar 4, 2026
Avg Cost/Share
$17.87
Shares
2,438
Total Value
$43,571.69
Owned After
0
SEC Form 4
Ribeiro Ramiro
Sell
Chief Medical Officer
EYPT Feb 17, 2026
Avg Cost/Share
$15.00
Shares
2,437
Total Value
$36,555.00
Owned After
0
SEC Form 4
Ribeiro Ramiro
Sell
Chief Medical Officer
EYPT Jan 5, 2026
Avg Cost/Share
$17.10
Shares
42,544
Total Value
$727,319.46
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Duker Jay S. | EYPT | President and CEO | Mar 16, 2026 | Buy | $13.15 | 1,500 | $19,723.80 | 100,665 | |
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Mar 4, 2026 | Sell | $17.87 | 2,438 | $43,571.69 | 0 | |
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Feb 17, 2026 | Sell | $15.00 | 2,437 | $36,555.00 | 0 | |
| Ribeiro Ramiro | EYPT | Chief Medical Officer | Jan 5, 2026 | Sell | $17.10 | 42,544 | $727,319.46 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 4, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 4, 2026 · 100% conf.
AI Prediction SELL
1D
-2.53%
$17.53
Act: -12.44%
5D
-8.80%
$16.40
Act: -17.11%
20D
-11.59%
$15.90
Price: $17.98 Prob +5D: 0% AUC: 1.000
0001193125-26-089856
8-K
0001314102false00013141022026-03-042026-03-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 04, 2026
EyePoint, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
000-51122
26-2774444
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
480 Pleasant Street
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 926-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
EYPT
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 4, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of EyePoint, Inc., dated March 4, 2026
104
Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EYEPOINT, INC.
Date:
March 4, 2026
By:
/s/ George O. Elston
George O. Elston Executive Vice President and Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 7, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 7, 2026 · 100% conf.
AI Prediction SELL
1D
-2.53%
$17.53
Act: -12.44%
5D
-8.80%
$16.40
Act: -17.11%
20D
-11.59%
$15.90
Price: $17.98 Prob +5D: 0% AUC: 1.000
0001193125-26-005418
8-K
0001314102false00013141022026-01-072026-01-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 07, 2026
EyePoint, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
000-51122
26-2774444
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
480 Pleasant Street
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 926-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
EYPT
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 7, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its preliminary December 31, 2025 cash, and certain other corporate updates. The amounts included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company’s audited financial statements for the year ended December 31, 2025. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the press release is filed as Exhibit 99.1 hereto.
The information included under Item 2.02 of this current report on Form 8-K, including Exhibit 99.1, is deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and, therefore, may be incorporated by reference in filings under the Securities Act of 1933, as amended. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of EyePoint, Inc. dated January 7, 2026
104
Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EYEPOINT, INC.
Date:
January 7, 2026
By:
/s/ George O. Elston
George O. Elston Executive Vice President and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001193125-25-265706
8-K
false000131410200013141022025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 05, 2025
EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
000-51122
26-2774444
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
480 Pleasant Street
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 926-5000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
EYPT
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of EyePoint Pharmaceuticals, Inc. dated November 5, 2025
104
Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EYEPOINT PHARMACEUTICALS, INC.
Date:
November 5, 2025
By:
/s/ George O. Elston
George O. Elston Executive Vice President and Chief Financial Officer
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
Reuters
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
➖
AI Sentiment
Neutral
4/10
Compare EYPT vs Leading Stocks
See how EYPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.